DataMEDS AI, Inc. filed a Form 8-K on November 20, 2026, disclosing that Co-Chief Executive Officer Gerald Commissiong purchased 5,000 shares of the company's common stock on the Nasdaq Capital Market at $1.09 per share on that same date.

Key Highlights

  • Buyer: Gerald Commissiong, Co-Chief Executive Officer of DataMEDS AI, Inc.
  • Shares purchased: 5,000 shares of common stock
  • Purchase price: $1.09 per share
  • Transaction date: November 20, 2026
  • Exchange: Nasdaq Capital Market (NASDAQ:MEDS)
  • Company classification: Emerging growth company, as indicated in the filing

DataMEDS AI Co-CEO Open-Market Share Purchase on November 20, 2026

According to the Form 8-K filed with the U.S. Securities and Exchange Commission on November 20, 2026, Gerald Commissiong, identified in the filing as the Co-Chief Executive Officer of DataMEDS AI, Inc., purchased 5,000 shares of the company's common stock. The filing states the transaction was executed on the Nasdaq Capital Market at a purchase price of $1.09 per share. The company's common stock carries a par value of $0.0001 per share and trades under the ticker symbol MEDS.

The disclosure was made under Item 8.01 (Other Events) of the Form 8-K. DataMEDS AI, Inc. is incorporated in Delaware, holds Commission File Number 001-42530, and is headquartered at 3000 Bayport Drive, Suite 950, Tampa, FL 33607, according to the filing. The report was signed on behalf of the registrant by Prashant Patel, President. The filing also indicates that DataMEDS AI, Inc. is an emerging growth company as defined under applicable securities regulations, and that it has not elected to use the extended transition period for complying with new or revised financial accounting standards.

What Was Disclosed

DataMEDS AI, Inc. reported via Form 8-K that its Co-CEO Gerald Commissiong purchased 5,000 shares of company common stock on the Nasdaq Capital Market at $1.09 per share on November 20, 2026. No additional transaction details were provided in the filing.